{"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the low number of events.","groupId":"OG000","lowerLimit":"10.85","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG001","lowerLimit":"10.16","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"The duration of stable disease was defined as the time between any two observations of objective disease progression (modified IWG criteria), starting from the first day of dosing with IP. Participants who maintained stable disease through the end of the treatment period were censored at the date of study termination.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were given oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG000","title":"Stable Disease (SD) Cohort: Oral Azacitidine"},{"description":"Participants were given oral azacitidine 100 mg, 150mg, or 200mg tablets BID on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG001","title":"Progressive Disease (PD) Cohort: Oral Azacitidine"},{"description":"Participants received 100 mg oral azacitidine (AZA) tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab (Durva) 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG002","title":"Stable Disease Cohort: Oral Azacitidine and Durvalumab"},{"description":"Participants received 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG003","title":"Progressive Disease Cohort: Oral Azacitidine and Durvalumab"}],"paramType":"MEDIAN","populationDescription":"The population includes participants who achieved stable disease as their best response.","reportingStatus":"POSTED","timeFrame":"Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms","title":"Kaplan-Meier Estimate of Duration of Stable Disease","type":"SECONDARY","unitOfMeasure":"Months"}